The Kallikrein Panel for prostate cancer screening: Its economic impact
Article first published online: 26 OCT 2013
© 2013 Wiley Periodicals, Inc.
Volume 74, Issue 3, pages 250–259, February 2014
How to Cite
Voigt, J. D., Zappala, S. M., Vaughan, E. D. and Wein, A. J. (2014), The Kallikrein Panel for prostate cancer screening: Its economic impact. Prostate, 74: 250–259. doi: 10.1002/pros.22746
- Issue published online: 13 JAN 2014
- Article first published online: 26 OCT 2013
- Manuscript Accepted: 30 SEP 2013
- Manuscript Received: 15 JUL 2013
- cost savings;
- clinical utility;
Current diagnostic testing for prostate cancer results in numerous unnecessary biopsy procedures and creates a substantial financial burden. A statistical prediction model for prostate cancer has been developed, based on four Kallikrein markers in blood. This systematic review and meta-analysis examines the aggregated results from published studies of the Kallikrein Panel.
Literature searches to identify relevant studies were conducted. A meta-analysis of the results was performed using inverse variance, mean difference with corresponding 95% confidence intervals (CI). The results of the meta-analysis were used to assess the Kallikrein Panel's effect on healthcare costs.
The Kallikrein Panel has been evaluated in more than 8,500 patients (2,780 with prostate cancer and 598 with high grade prostate cancer). Meta-analysis demonstrates a statistically significant improvement of 8–10% in predictive accuracy. In addition, 48% to 56% of current prostate biopsies could be avoided. Use of the Kallikrein Panel could result in annual US savings approaching $1 billion.
The Kallikrein Panel has the potential to improve patient outcomes and reduce costs. The panel provides significantly improved specificity. Because the Kallikrein Panel has been studied in a range of clinical settings, it is a test that could be readily and widely used in practice. Prostate 74:250–259, 2014. © 2013 Wiley Periodicals, Inc.